Pyxis Oncology is trading 5.8% down at $2.80 as the stock undergoes a pullback following a sharp multi-day rally.
- The move likely reflects profit-taking and consolidation after recent sector-driven gains across the biotech industry.
- There are no new company-specific announcements or regulatory filings driving today’s price action.
- The decline does not appear to be linked to any change in the company’s underlying fundamentals or clinical pipeline outlook.